The "Registered Direct Offering" took place on March 27....There were 5.6 million shares in that offering. If you do an Accumulation/Distribution chart you can see the selling begins after the first week of April (about 100 days) and NEVER ONCE let's up through today....They bought at $2.60 and at current levels there is little margin to make them anything at all. Of course below $2.60,,they get nothing or lose. I suppose it's possible they have sold and made enough to take a loss if any remaining shares exist. But in my opinion, the selling pressure from the "offering" and the "under $1.00 club" has been substantial since April. I don't see how there could be much left and the volume would seem to support that. I suppose this is what it takes building from the ground up.
It's not just another, their treatment works at 98% eficacy....They are NOT cleared for breast but they ARE working on it....Nonetheless, they ARE cleared for brain cancer, gynecological cancer, ocular cancer, prostate cancer and Lung results are soon to be announced......I can't believe a company with NO FDA approval trades more than a company WITH FDA approval and working at 98% eficacy.
I 'replied' just to repost this,,,,"just because".....From my perspective a 'cure for cancer' is a 'cure for cancer' and 98% eficacy is nothing to laugh at..
"Isoray" (ISR) is currently working on "Breast",,,,They are an isotope seed company using Cesium 131 and it's already FDA approved for prostate cancer, brain cancer, ocular cancer & gynecological cancer....They are working on "Breast Cancer".......They are very close to releasing "Lung Cancer" results....But their treatment is a "process" of planting radiation seeds in the wound after surgery rather than taking a pill....But it works at 98% efficiency....Which makes me wonder WHY Isoray doesn't trade at much higher levels than it does.
Thank you amacall....The way I see it is if it "cures cancer" then it "cures cancer"....I don't really understand why the 'method' would matter to Wall Street....But I think it kinda relates to how things work in general,,,,perhaps it's "who you know,,,and not necessarily what you know"......We'll see.
Holy smoke,,,there's going to be some long faces tomorrow...I would love to be a fly on the wall. Thanks!!
That's what I don't get.....Cesium 131 has 98% efficacy and is much less invasive than proton therapy...So if any stock should be trading at $50+,,,,Isoray is it!!!....I don't get it.
WOW.....Thanks for that answer...I'm not that intimate with the inner workings of the market...I simply buy long and hold so any of that information gives me an idea of what might be taking place and I will be watching closely tomorrow as I'm sure many people will be.
Thank you for that complete answer....I'm curious though,,,do you think there are people short a 1000 shares of this stock? I have no idea and obviously it would be a substantial loss. But I've never seen anything fly like this after hours.
I don't short so I don't have any experience with it but I'm curious to know....If someone was short at $59.00 today and after hours the stock raises to $179.00......How much would they lose per 1 share of stock?
All over a 33% improvement in breast cancer results when ISR is working at 98% + in all other areas and they are currently working on breast. Unbelievable.
It's FDA approved with proven results and we're at $2.75/share.....The thing that gets me is there are biotechs with NO product on the market,,,still in trials,,,,and ZERO revenues,,,,but they are affiliated with a big pharmaceutical company of some sort and their share price inflates because of it. ISR actually has product that other big pharmas could use but why is there no mention of "looking to partner" by Babcock?
I thought maybe Lung data would be out this week. I would think there has been enough time to compile and process it. But perhaps they are waiting on a "timing" issue for whatever reason.